JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at human (pKi=9.24) H3 receptor and was developed by Johnson & Johnson Pharmaceutical. During preclinical studies were shown that JNJ-5207852 might be useful in the treatment of cognitive impairment in epilepsy. On animal models was discovered, that this compound readily penetrates the brain tissue after subcutaneous administration.